-
Aging: Sex differences in major cardiovascular outcomes and fractures in patients with subclinical thyroid dysfunction
Time of Update: 2023-01-04
Objective: Given the few reports of sex-related differences in the association of subclinical SH and SCH with chronic kidney disease, cognitive decline, and decreased bone mineral density, we conducted a systematic review and meta-analysis to assess differences in STDs associated with major adverse cardiovascular events (MACEs) and fractures between men and women.
-
eClinicalMed: Age, sex, BMI, etc. of cardiovascular benefits in T2DM patients receiving SGLT2i and GLP-1 RA
Time of Update: 2022-10-19
The study aims to provide information by age (< 65 v>s 65 years and < 75 vs > 75 years), gender (male vs female), race (black vs white, black vs Asian, white vs Asian), body mass index (BMI< 30kg/m 2 vs ≥30kg/m2 Overall hazard ratio estimates for MACE associated with SGLT2i and GLP-1 receptor agonists stratified by diabetes course (< 10 years versus ≥10 years).
-
JCEM: Body mass index and contraceptives affect age, sex and puberty-adjusted reference ranges for IGF-I and IGFBP-3
Time of Update: 2022-04-24
Objectives : We asked whether BMI, contraceptives (CDs) and hormone replacement therapy (HRT) have a potential impact on the interpretation of the new age-, sex- and puberty-adjusted reference ranges for serum levels of IGF-I and IGFBP-3 .
-
Front.aging-neurosci - Sex-related differences in regional brain glucose metabolism in the normal aging brain
Time of Update: 2022-03-04
Differences in metabolism between men and women beforeThe authors found that brain metabolism in the caudate nucleus decreased to varying degrees in both the male 60-year-old group and the 70-year-old group, while the occipital region of the female 60-year-old group showed a specific decline .
-
-experienced patients with metastatic gastric/gastroesophageal junction cancer (mGC/GEJC) in different age subgroups of the phase III TAGS study sex
Time of Update: 2022-01-22
Subgroup analysis of the TAGS study showed that FTD/TPI therapy in patients with mGC/GEJC who received 2 or more previous treatments was still effective and tolerable regardless of age .